Dyadic International/ US26745T1016 /
5/31/2024 9:50:05 PM | Chg. -0.20 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
2.20USD | -8.33% | 407 Turnover: 903.10 |
-Bid Size: - | -Ask Size: - | 2.29 | 2.19 |
GlobeNewswire
5/14
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
GlobeNewswire
3/26
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communica...
GlobeNewswire
3/21
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
GlobeNewswire
3/14
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 20...
GlobeNewswire
3/11
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Acce...
GlobeNewswire
3/11
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-T...
GlobeNewswire
2/28
Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vacc...
GlobeNewswire
2/21
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Thr...
GlobeNewswire
2/13
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality...
GlobeNewswire
2/6
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Comp...
GlobeNewswire
11/29/2023
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Fi...
GlobeNewswire
11/20/2023
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
GlobeNewswire
11/10/2023
The Benchmark Company Announces Upcoming 12th Annual Discovery One-on-One Investor Conference
GlobeNewswire
11/8/2023
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress